Materia Medica Malaysiana

TH Group invests RM40m in NCI expansion

Sabah- based TH Group Bhd has invested RM40mil in the expansion of the NCI Cancer Hospital (NCI), group general manager Angie Ang said.
She said the investment was for both the expansion of the hospital building and equipment.
“Our capacity at the moment is probably about 500 to 700 patients per year. With the expansion, we hope to increase it to several thousand,” she told reporters after the signing of a collaboration understanding between Asiaprise Biotech Sdn Bhd and Health Scan Malaysia Sdn Bhd in Kuala Lumpur yesterday.
Asiaprise Biotech, a subsidiary of TH Group, is involved in pharmaceutical trading/distribution, and investment in biotech/healthcare-related activities. The expansion of NCI is expected to be completed in September.
Asiaprise Biotech executive chairman Dr Kim Tze Tan said that through the collaboration agreement, the two parties would work together to provide optimum medical care to patients from both centres, particularly in the disciplines of oncology and cardiology.
He said NCI would provide follow-up care for Health Scan Malaysia's patients who required further diagnosis or treatment in respect of cancer.
“NCI will leverage on Health Scan Malaysia's expertise in the area of cardiology to provide follow-up care for its patients who may be diagnosed with cardiac complications,” he said.
NCI is Malaysia's first private cancer centre that offers cancer treatment and clinical research, while Health Scan Malaysia was conceived as a premier medical centre to offer comprehensive health screening using the most advanced technology. – Bernama